⌘K
t
Faron Pharmaceuticals Ltd. announced its financial calendar for 2025 on December 13, 2024. The company will release its full year 2024 financial statement and annual report on February 27, 2025, and its half-year financial report for January 1 to June 30, 2025, on August 27, 2025. The Annual General Meeting is planned to be held on March 21, 2025.
| Date | 13 Dec 2024 |
| Time | 07:00:02 |
| Category | Miscellaneous |
| ID | 9181P |
Faron Pharmaceuticals Ltd.
("Faron" or "the Company")
Faron's Financial Calendar for 2025
Company announcement, 13 December 2024
TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the following dates for the Company's financial reporting in 2025:
|
February 27 |
Financial statement release for the full year 2024 and Annual Report 2024 including financial statements for the full year |
|
August 27 |
Half-year financial report for the period January 1 to June 30, 2025
|
The Annual General Meeting is planned to be held on March 21, 2025. A separate stock exchange notice will be issued by Faron's Board of Directors to convene the meeting.
For more information please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@icrhealthcare.com
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213 0880
Peel Hunt LLP, Broker
Christopher Golden, James Steel
Phone: +44 (0) 20 7418 8900
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.